Interferon‐β1a therapy in human T‐lymphotropic virus type I–associated neurologic disease
- 22 March 2005
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 57 (4) , 526-534
Abstract
Human T‐lymphotropic virus type I (HTLV‐I)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an immune‐mediated inflammatory disorder of the central nervous system. Immune activation in the host, which results from high levels of persistent antigenic stimulation and from transactivation of host immunoregulatory genes by HTLV‐I, appears important in the pathogenesis of HAM/TSP. In a single‐center, open‐label trial, 12 patients with HAM/TSP were treated with doses of interferon‐β1a of up to 60μg twice weekly, based on its antiviral and immunomodulatory effects. Primary end points were immunological and virological measures that are potential biomarkers for HAM/TSP. Interferon‐β1a therapy reduced the HTLV‐I tax messenger RNA load and the frequency of potentially pathogenic HTLV‐I–specific CD8+ cells. The HTLV‐I proviral DNA load remained unchanged. Spontaneous lymphoproliferation, a marker of T‐cell activation in HAM/TSP, also was reduced. Some measures of motor function were improved, and no significant clinical progression occurred during therapy. These results indicate that interferon‐β1a may beneficially affect the immune mechanisms central to the pathogenesis of HAM/TSP. Ann Neurol 2005;57:526–534Keywords
This publication has 32 references indexed in Scilit:
- Decreased Human T Lymphotropic Virus Type I (HTLV‐I) Provirus Load and Alteration in T Cell Phenotype after Interferon‐α Therapy for HTLV‐I–Associated Myelopathy/Tropical Spastic ParaparesisThe Journal of Infectious Diseases, 2004
- Immunopathogenesis of Human T Cell Lymphotropic Virus Type I–Associated Neurologic DiseaseThe Journal of Infectious Diseases, 2002
- Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tacAnnals of Neurology, 1998
- Phenotypic and Functional Separation of Memory and Effector Human CD8+ T CellsJournal of Experimental Medicine, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV-I-associated myelopathy/tropical spastic paraparesis patients.Journal of Clinical Investigation, 1994
- High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease.Journal of Experimental Medicine, 1993
- HTLV‐I Uveitis: A Distinct Clinical Entity Caused by HTLV‐IJapanese Journal of Cancer Research, 1992
- Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological diseaseNature, 1990
- Direct activation of resting T lymphocytes by human T-lymphotropic virus type INature, 1987